Cost-Effectiveness of Korea's National Cervical Cancer Screening Program

  • Cho, Eun (College of Pharmacy, Sookmyung Women's University) ;
  • Kang, Moon Hae (Graduate School of Yonsei University) ;
  • Choi, Kui Son (National Cancer Control Research Institute, National Cancer Center) ;
  • Suh, MiNa (National Cancer Control Research Institute, National Cancer Center) ;
  • Jun, Jae Kwan (National Cancer Control Research Institute, National Cancer Center) ;
  • Park, Eun-Cheol (Institute of Health Services Research, Yonsei University)
  • Published : 2013.07.30


Background: Cervical cancer, which is common in developing countries, is also a major health issue in Korea. Our aim was to evaluate the cost-effectiveness of Korea's National Cancer Screening Program (NCSP), implemented in 1999. Materials and Methods: The target population was Korean women 30 years or over who were invited to take part in the NCSP in 2002-2007. By merging NCSP records with Korean Central Cancer Registry data, patients diagnosed with cervical cancer who had been screened were assigned to a "screened group," while patients diagnosed elsewhere were assigned to a "non-screened group." Clinical outcomes were measured in terms of life-years saved (LYS), derived from 5-year mortality rates supplied by the Korean National Health Insurance Corporation and National Statistical Office. Direct and travel costs associated with screening were evaluated from the perspective of the payer, the NCSP. Results: A diagnosis via screening was associated with 2.30 LYS, and the incremental cost-effectiveness ratio (ICER) estimate for screening was 7,581,679 KW/LYS (6,727 USD/LYS). ICER estimates were lower for older patients (${\geq}$ 50 years) than younger patients (4,047,033 KW/LYS vs 5,680,793 KW/LYS). The proportion of early-stage cancers detected was 16.3% higher in the screened group. Conclusions: In light of Korea's per capita gross domestic product (32,272 USD in 2012), the current NCSP's incremental cost per LYS appears acceptable.


Cost-effectiveness;mass screening;cervical cancer;pap smear;Korea


Supported by : Cancer Control, Ministry of Health and Welfare, Korean Foundation for Cancer Research


  1. Woo PP, Kim JJ, Leung GM (2007). What is the most costeffective population-based cancer screening program for Chinese women? J Clin Oncol, 25, 617-24.
  2. Yamamoto N, Mori R, Jacklin P, et al (2012). Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis. BJOG, 119, 177-86.
  3. Zhao FH, Chen JF, Gao XH, et al (2012). Effectiveness and health economic analysis of strategies on cervical cancer screening and early diagnosis and treatment. Zhonghua Zhong Liu Za Zhi, 34, 632-6.
  4. Kim SJ, Namkoong SE, Lee JM, et al (1994). Cervical cancer control in Korea: colposcopy/cervicograph/cytology. Arch AIDS Res, 8, 101-11.
  5. Kim Y, Jun JK, Choi KS, et al (2011). Overview of the National Cancer screening programme and the cancer screening status in Korea. Asian Pac J Cancer Prev, 12, 725-30.
  6. Konno R, Shin H-R, Kim Y-T, et al (2008). Human Papillomavirus Infection and Cervical Cancer Prevention in Japan and Korea. Vaccine, 26, 30-42.
  7. Koong SL, Yen AM, Chen TH (2006). Efficacy and costeffectiveness of nationwide cervical cancer screening in Taiwan. J Med Screen, 13, 44-7.
  8. Korean Statistical Information Service (KOSIS) (2012).
  9. Lee HY, Lim SM, Han MA, et al (2011). Assessment of participant satisfaction with upper gastrointestinal endoscopy in South Korea. World J Gastroenterol, 17, 4124-9.
  10. Levin CE, Sellors J, Shi JF, et al (2010). Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer, 127, 1404-11.
  11. Park MJ, Park EC, Choi KS, et al (2011). Sociodemographic gradients in breast and cervical cancer screening in Korea: the Korean National Cancer Screening Survey (KNCSS) 2005-2009. BMC Cancer, 11, 257.
  12. Praditsitthikorn N, Teerawattananon Y, Tantivess S, et al (2011). Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics, 29, 781-806.
  13. Razak NA, Mn K, Zubairi YZ, et al (2013). Estimating the fiveyear survival of cervical cancer patients treated in hospital universiti sains malaysia. Asian Pac J Cancer Prev, 14, 825-8.
  14. Sato S, Matsunaga G, Konno R, et al (1998). Mass screening for cancer of the uterine cervix in Miyagi Prefecture, Japan. Effects and problems. Acta Cytol, 42, 299-304.
  15. Sharma M, Ortendahl J, van der Ham E, et al (2012). Costeffectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG, 119, 166-76.
  16. Shi JF, Canfell K, Lew JB, et al (2011). Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer, 11, 239.
  17. Shin HR, Jung KW, Won YJ, et al (2007). National cancer incidence for the year 2002 in Korea. Cancer Res Treat, 39, 139-49.
  18. Statistics Korea. (2012). Consumer Price Index in November 2012: Price Statistics Division, Economic Statistics Bureau.
  19. Jung KW, Yim SH, Kong HJ, et al (2007). Cancer survival in Korea 1993-2002: a population-based study. J Korean Med Sci, 22, 5-10.
  20. Kim JH, Kim IW, Kim YW, et al (2013). Comparison of single-, double- and triple-combined testing, including Pap test, HPV DNA test and cervicography, as screening methods for the detection of uterine cervical cancer. Oncol Rep, 29, 1645-51.
  21. Chen MK, Hung HF, Duffy S, et al (2011). Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination. J Eval Clin Pract, 17, 1050-8.
  22. Cho E, Kang MH, Choi KS, et al (2013). Cost-effectiveness Outcomes of the National Gastric Cancer Screening Program in South Korea. Asian Pac J Cancer Prev, 14, 2533-40.
  23. Chung HH, Jang MJ, Jung KW, et al (2006). Cervical cancer incidence and survival in Korea: 1993-2002. Int J Gynecol Cancer, 16, 1833-8.
  24. Ezat WP, Aljunid S (2010). Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia. Asian Pac J Cancer Prev, 11, 79-90.
  25. Flores YN, Bishai DM, Lorincz A, et al (2011). HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico. Cancer Causes Control, 22, 261-72.
  26. Forouzanfar MH, Foreman KJ, Delossantos AM, et al (2011). Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. The Lancet, 378, 1461-84.
  27. Gravitt PE, Paul P, Katki HA, et al (2010). Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India. PLoS One, 5, 13711.
  28. Hahm MI, Choi KS, Lee HY, et al (2011). Who participates in the gastric cancer screening and on-time rescreening in the National Cancer Screening Program? A population-based study in Korea. Cancer Sci, 102, 2241-7.
  29. Han MA, Jun JK, Choi KS, et al (2012). Satisfaction in the National Cancer Screening Program for breast cancer with and without clinical breast examination. Asian Pac J Cancer Prev, 13, 63-7.
  30. Jun JK, Choi KS, Jung KW, et al (2009). Effectiveness of an organized cervical cancer screening program in Korea: results from a cohort study. Int J Cancer, 124, 188-93.
  31. Jung KW, Shin HR, Kong HJ, et al (2010). Long-term trends in cancer mortality in Korea (1983-2007): a joinpoint regression analysis. Asian Pac J Cancer Prev, 11, 1451-7.

Cited by

  1. Mortality of Major Cancers in Guangxi, China: Sex, Age and Geographical Differences from 1971 and 2005 vol.15, pp.4, 2014,
  2. Need to Pay More Attention to Attendance at Follow-Up Consultation after Cancer Screening in Smokers and Drinkers vol.16, pp.1, 2015,
  3. Strategic Distributional Cost-Effectiveness Analysis for Improving National Cancer Screening Uptake in Cervical Cancer: A Focus on Regional Inequality in South Korea vol.50, pp.1, 2018,